|
Lotus Pharmaceuticals, Inc. (LTUS) Receives Phase I Approval for Asthma Drug
International Business Times Lotus Pharmaceuticals, Inc. said that research conducted by a third party indicated that the Asthma market in China is approximately $300 million annually, … Lotus Pharmaceuticals Receives SFDA Approval to Initiate Phase I Clinical … |
View full post on asthma – Google News